Pharmaceutical research and development (R&D) is unlikely to be significantly impacted by most favored nation (MFN) pricing, according to industry experts. The US bears the highest drug costs globally ...

State policymakers are weighing imposing capitalization of R&D costs — for illusory budget savings and against federal law. Capitalization will crush state business.

Tustin-based Peregrine Pharmaceuticals Inc. said Friday that higher research and staffing costs led to a larger loss in the quarter ended Oct. 31. Peregrine, which is developing drugs to treat ...

The U.S. Capitol in Washington, DC. A bipartisan group of lawmakers has reintroduced legislation to allow immediate expensing of research and development costs, all the way back to 2022 when the tax ...

Two major pieces of legislation that were passed in 2025 — one federal and one state — will positively impact Connecticut businesses that engage in research and development in 2026. William Claffey ...

The “One Big, Beautiful Bill” budget reconciliation bill that recently cleared the U.S. House of Representatives contains especially notable developments for early-stage biotech and life sciences ...

DUBLIN--(BUSINESS WIRE)--The "Pharmaceutical R&D Outsourcing Market - Focused Insights 2024-2029" report has been added to ResearchAndMarkets.com's offering. The Pharmaceutical R&D Outsourcing Market ...